Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

Background Neoadjuvant endocrine therapy (NET) can improve surgical outcomes in postmenopausal patients with hormone receptor-positive breast cancer. The Ki67 labelling index after NET has a better prognostic power than that at baseline. However, it remains unknown whether a multigene assay with pos...

Full description

Bibliographic Details
Main Authors:	Hiroji Iwata, Takayuki Ueno, Shigehira Saji, Norikazu Masuda, Katsumasa Kuroi, Nobuaki Sato, Hiroyuki Takei, Yutaka Yamamoto, Shinji Ohno, Hiroko Yamashita, Kazufumi Hisamatsu, Kenjiro Aogi, Hironobu Sasano, Masakazu Toi
Format:	Article
Language:	English
Published:	Elsevier 2019-02-01
Series:	ESMO Open
Online Access:	https://esmoopen.bmj.com/content/4/1/e000476.full

Similar Items

Early use of steroids affects immune cells and impairs immunotherapy efficacy
by: Hiroji Iwata, et al.
Published: (2019-02-01)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2018-07-01)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
by: Nobuaki Sato, et al.
Published: (2019-09-01)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
by: Takayuki Ueno, et al.
Published: (2019-02-01)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
by: Eriko Tokunaga, et al.
Published: (2021-08-01)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
by: Masuda Norikazu, et al.
Published: (2010-02-01)

Personalized Therapy for Breast Cancer: How Long More to be There?
by: Elham Fakhrejahani, et al.
Published: (2014-11-01)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
by: Masato Takahashi, et al.
Published: (2020-07-01)

Impact of body mass index on breast cancer in accordance with the life-stage of women
by: Reiko eSuzuki, et al.
Published: (2012-10-01)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
by: Aogi, K., et al.
Published: (2022)

The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients
by: Sunao Tanaka, et al.
Published: (2017-04-01)

Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model
by: Takada Masahiro, et al.
Published: (2012-06-01)

Neoadjuvant endocrine therapy
by: S. Johnston
Published: (2021-04-01)

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
by: Hiroyasu Yamashiro, et al.
Published: (2018-07-01)

Neoadjuvant endocrine therapy in breast cancer patients
by: Raquel Alexandra Lobo Cardoso
Published: (2019)

Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01)

MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy
by: Takeda, Kazuna
Published: (2012)

Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
by: Hitoshi Inari, et al.
Published: (2020-09-01)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
by: Florence Lerebours, et al.
Published: (2021-02-01)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
by: Covadonga Martí, et al.
Published: (2021-05-01)

EARLY PREDICTION OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED BREAST CANCER USING MRI
by: NAGANAWA, SHINJI, et al.
Published: (2011)

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy
by: Shunsuke Ueki, et al.
Published: (2020-02-01)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
by: Fumikata Hara, et al.
Published: (2010-04-01)

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
by: Junko Suga, et al.
Published: (2018-12-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
by: Giacomo Barchiesi, et al.
Published: (2020-05-01)

Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System
by: Takayuki Ueno, et al.
Published: (2015-01-01)

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
by: Yurina Maeshima, et al.
Published: (2021-05-01)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
by: Toshinari Yamashita, et al.
Published: (2020-06-01)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
by: Toshinari Yamashita, et al.
Published: (2020-05-01)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-07-01)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
by: Hee Jeong Kim, et al.
Published: (2020-05-01)

Experimental study on neutron energy spectra during moderation in the thermal reactor
by: Kuroi, Hideo
Published: (2016)

Detection of the transient conformational fluctuation of blue light sensor protein TePixD and its functional importance
by: Kuroi, Kunisato
Published: (2015)

Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored
by: Elham Fakhrejahani, et al.
Published: (2012-01-01)

Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
by: Naiki Taku, et al.
Published: (2012-12-01)

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
by: Sarah Boughdad, et al.
Published: (2020-01-01)

A case of Adrenocoricotrophic hormone -independent bilateral adrenocortical macronodular hyperplasia concomitant with primary aldosteronism
by: Mao Tokumoto, et al.
Published: (2017-09-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
by: Sungchan Gwark, et al.
Published: (2021-09-01)

Concentration profiles of ions and particles under hydrodynamic focusing in Y-shaped square microchannel
by: Norikazu Sato, et al.
Published: (2021-01-01)